The 6-minute walk test in Duchenne/Becker muscular dystrophy: Longitudinal observations

Muscle and Nerve

Volumn 42, Issue 6, 2010, Pages 966-974

  Mcdonald, Craig M ^a   Henricson, Erik K ^a   Han, Jay J ^a   Abresch, R Ted ^a   Nicorici, Alina ^a   Atkinson, Leone ^b   Elfring, Gary L ^b   Reha, Allen ^b   Miller, Langdon L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PTC THERAPEUTICS   (United States)

Author keywords

Case control study; Child; Disabled children; Exercise test; Gait disorders; Neurologic

Indexed keywords

AGE; ARTICLE; BECKER MUSCULAR DYSTROPHY; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; LEG LENGTH; LONGITUDINAL STUDY; MALE; MOBILIZATION; NEUROMUSCULAR FUNCTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIX MINUTE WALK TEST; STANDING; VALIDITY;

BODY HEIGHT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GAIT; HUMANS; MALE; MUSCULAR DYSTROPHY, DUCHENNE; WALKING;

EID: 78649647875     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21808     Document Type: Article

References (32)

1. Lapidos KA, Kakkar R, McNally EM. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res 2004;94:1023-1031. (Pubitemid 38579696)
2. Ciafaloni E, Fox DJ, Pandya S, Westfield CP, Puzhankara S, Romitti PA, et al. Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 2009;155:380-385.
3. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Florence J, et al. Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 1989;39: 475-481.
4. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley R, Miller JP, et al. Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
5. McDonald CM, Abresch RT, Carter GT, Fowler WM Jr, Johnson ER, Kilmer DD, et al. Profiles of neuromuscular diseases. Duchenne muscular dystrophy. Am J Phys Med Rehabil 1995;74(suppl):S70-S92.
6. Boland BJ, Silbert PL, Groover RV, Wollan PC, Silverstein MD. Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol 1996;14:7-12. (Pubitemid 26069525)
7. Kohler M, Clarenbach CF, Bahler C, Brack T, Russi EW, Bloch KE. Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 2009;80:320-325.
8. Centers for Disease Control and Prevention (CDC). Prevalence of Duchenne/Becker muscular dystrophy among males aged 5-24 years - four states, 2007. MMWR Morbid Mortal Wkly Rep 2009;58: 1119-1122.
9. Moxley RT III, Ashwal S, Pandya S, Connolly A, Florence J, Mathews K, et al. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13-20.
10. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;23:CD003725.
11. Nelson SF, Crosbie RH, Miceli MC, Spencer MJ. Emerging genetic therapies to treat Duchenne muscular dystrophy. Curr Opin Neurol 2009;22:532-538.
12. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
13. Kierkegaard M, Tollback A. Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord 2007;17:943-949.
14. Laforet P, Clemens PR, Corzo D, Escolar D, Florence J, van der Ploeg A, et al. Safety and efficacy results from a randomized, doubleblind, placebo-controlled study of alglucosidase alfa for the treatment of Pompe disease in juveniles and adults. Neuromuscul Disord 2008;18:832.
15. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903. (Pubitemid 34984638)
16. Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis. I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 2004;144:581-588.
17. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 2006;8:465-473.
18. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010;41:500-510.
19. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007;447:87-91.
20. PTC Therapeutics. Phase 2b study of PTC124 in Duchenne/Becker muscular dystrophy (DMD/BMD). Available at: http://clinicaltrials. gov/ct2/show/ NCT00592553.
21. Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006;148:533-539.
22. McDonald CM, Widman L, Abresch RT, Walsh SA, Walsh DD. Utility of a step activity monitor for the measurement of daily ambulatory activity in children. Arch Phys Med Rehabil 2005;86:793-801. (Pubitemid 40487849)
23. McDonald CM, Widman LM, Walsh DD, Walsh SA, Abresch RT. Use of step activity monitoring for continuous physical activity assessment in boys with Duchenne muscular dystrophy. Arch Phys Med Rehabil 2005;86:802-808.
24. Florence J, Abresch RT, Eagle M, Gappmaier E, Glanzman AM, Henricson E, et al. Reproducibility and correlation of pretreatment outcome measures in phase 2b study of ataluren (PTC124™) in nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD) Neuromuscul Disord 2009;19:611-612.
25. Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-minute walk test in children and adolescents. J Pediatr 2007;150:395-399.
26. Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med 2007;176:174-180. (Pubitemid 47057854)
27. Lammers AE, Hislop AA, Flynn Y, Haworth SG. The 6-minute walk test: normal values for children of 4-11 years of age. Arch Dis Child 2008;93:464-468. (Pubitemid 352025761)
28. Lexell JE, Downham DY. How to assess the reliability of measurements in rehabilitation. Am J Phys Med Rehabil 2005;84:719-723.
29. Hodgson S, Hart K, Abbs S, Heckmatt J, Rodillo E, Bobrow M, et al. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy J Med Genet 1989;26:682-693.
30. Sutherland DH, Olshen R, Cooper L, Wyatt M, Leach J, Mubarak S, et al. The pathomechanics of gait in Duchenne muscular dystrophy. Dev Med Child Neurol 1981;23:3-22. (Pubitemid 11179345)
31. D'Angelo MG, Berti M, Piccinini L, Romei M, Guglieri M, Bonato S, et al. Gait pattern in Duchenne muscular dystrophy. Gait Posture 2009;29:36-41.
32. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 1997;155:1278-1282.